Free Shipping on Orders Over $75! Ends January 31st.

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to November 2015

“To Grow Old Without Disease”

Headline news story in The Wall Street Journal

November 2015

By William Faloon

William Faloon
William Faloon

An article in the Wall Street Journal describes a group of academic researchers who are seeking to initiate a human study where a single pill will be tested to see if it will prevent or delay the most debilitating diseases of aging.1

These top-level scientists describe findings from published studies that support the anti-aging effects of this single drug. These researchers boldly proclaim:

“Aging is the major risk factor for all these diseases—heart disease, cancer, diabetes, and Alzheimer’s… If you want to make a real impact you have to modulate the risk of aging and by that the risk for all those diseases of aging.”

What makes the above statement so unique is that today’s medical mainstream does not recognize aging as a disease. This conventional view is changing, however, as prominent scientists’ state that “ fighting every major disease of old age is not a winnable strategy.”2 They argue that if:

We lower the risk of heart disease, somebody lives long enough to get cancer. If we reduce the risk of cancer, somebody lives long enough to get Alzheimer’s disease… We are suggesting that the time has arrived to attack them all by going after the biological process of aging.2

In case you haven’t guessed it by now, the “pill” these scientists want to test in a human anti-aging study is the AMPK-activating drug metformin.

If you go back to the March 1995 issue of this magazine, you’ll see metformin listed in a group of recommended offshore anti-aging therapies. We were harshly persecuted by the FDA for daring to do this. We’ve since published dozens of articles urging members to ask their doctor to prescribe metformin to prevent age-related disease.

Those not able to secure a physician’s prescription learned last year of AMPK-activating nutrients that compared favorably to metformin in side-by-side research.3

The mainstream and even the FDA may finally be catching on to the deadly impact of loss of AMPK activity. It’s a shame that it has taken 20 years for researchers to want to initiate a human study of the anti-aging properties of metformin. The scientific data has been so clearly evident for so long.

Widespread use of AMPK-activating compounds could be a game-changing breakthrough that, as the Wall Street Journal stated could, “increase the number of years of healthy, independent living.1

The first article in this month’s edition describes the profound age-delaying and age-reversing effects that occur in response to activating one’s cellular AMPK.

This month’s issue also features eye-opening reports about newly discovered benefits of boron and selenium. The good news is that most readers of this magazine have been obtaining optimal forms of these minerals for many years.

The recognition of the age-delaying benefits of metformin is a major vindication of Life Extension’s long- standing position for people to take AMPK-activating compounds to extend their healthy life spans.

For longer life,

For Longer Life

William Faloon

References

  1. “To Grow Old Without Disease.” The Wall Street Journal. 2015 March 16.
  2. Available at: https://www.fightaging.org/archives/2015/03/fight-aging-newsletter-march-23rd-2015.php. Accessed May 19, 2015
  3. Available at: http://www.lifeextension.com//Magazine/2014/SS/AMPK/Page-01. Accessed May 19, 2015.